PROCEPT BioRobotics Corporation

Background

Company Name	PROCEPT BioRobotics Corporation
Stock Symbol	PRCT
Class Period	February 28, 2024 to February 25, 2026
Lead Plaintiff Motion Deadline	September 22, 2026
Court	N.D. Cal.

Submit Your Information

If you suffered a loss on your PROCEPT BioRobotics Corporation investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before February 28, 2024?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On August 6, 2025, Procept reported second quarter 2025 financial results, including that it expected to ship approximately 13,350 handpieces in the following quarter, significantly below consensus estimates. The guidance also implied that Procept would need to increase fourth quarter handpiece sales by approximately 25% year over year to meet its annual unit sales guidance. In addition, the Company announced that it was eliminating the position of Chief Commercial Officer to strengthen its commercial execution.

On this news, Procept’s stock price fell $6.10 or 13.35% to close at $39.59 on August 7, 2025, thereby injuring investors.

Then, on November 4, 2025, Procept reported third quarter 2025 financial results, revealing that it sold only 13,225 handpieces during the quarter, below the sales guidance issued during the prior quarter. During the accompanying earnings call, the Company reduced its annual handpiece sales guidance by 1,000 units, and admitted that customers were likely carrying excess inventory.

On this news, Procept’s stock price fell $3.41 or 9.74%, to close at $31.61 per share on November 5, 2025, further injuring investors.

Finally, on February 25, 2026, Procept reported fourth quarter and full-year 2025 financial results, revealing cumulative excess field inventory of more than 10,000 units, and that U.S. handpiece sales declined nearly 30% to approximately 9,400 units in the fourth quarter. During the accompanying earnings call, management further revealed that Procept was eliminating a longstanding discount program that had encouraged customers to make bulk purchases near the end of each quarter and acknowledged that handpiece sales had historically exceeded procedure volumes by 8% to 16%.

On this news, Procept’s stock price fell $4.21 or 15.12% to close at $23.63 on February 26, 2026, further injuring investors.

Submit Your Information